Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
4 hedge funds and large institutions have $957M invested in Sinovac Biotech, Ltd in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 5 closing their positions.
152% more capital invested
Capital invested by funds: $380M → $957M (+$577M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
56% less funds holding
Funds holding: 9 → 4 (-5)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$8K |
SVA Hedge Fund Activity: Q1 2023 in Review
4 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2023, worth a combined $957M — up 152% from $380M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SVA and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was IFP Advisors, exiting entirely with an estimated $8K sold.
- 4 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2023, down from 9 in Q4 2022.
- Funds reported $957M of Sinovac Biotech, Ltd stock for Q1 2023, up 152% quarter-over-quarter.
- 0 funds opened new Sinovac Biotech, Ltd positions in Q1 2023 and 5 closed out, a net change of -5 holders.
- The largest Sinovac Biotech, Ltd seller in Q1 2023 was IFP Advisors, an estimated $8K sold.
Based on aggregated 13F filings for Q1 2023.